VestGen Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14.1M Sell
12,221
-550
-4% -$649K 0.44% 47
2026
Q2
$15.3M Buy
12,771
+3,455
+37% +$3.53M 0.45% 45
2026
Q1
$9.22M Buy
9,316
+2,153
+30% +$2.18M 0.25% 84
2025
Q4
$7.7M Sell
7,163
-5,075
-41% -$4.85M 0.33% 77
2025
Q3
$9.34M Sell
12,238
-5,032
-29% -$3.74M 0.31% 68
2025
Q2
$13.5M Buy
17,270
+3,084
+22% +$2.4M 0.54% 40
2025
Q1
$11.7M Buy
+14,186
New +$11.8M 0.53% 40

Other funds holding LLY

VestGen Advisors's LLY Position: Q3 2026 in Review

VestGen Advisors reduced its Eli Lilly (LLY) stake by 4.3% in Q3 2026, selling an estimated $649K and leaving 12,221 shares worth $14.1M. The position accounts for 0.44% of the portfolio, ranked #47.

VestGen Advisors first reported a position in LLY in Q1 2025 and has held it in 7 quarters since. The position peaked at $15.3M in Q2 2026. 2,846 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • VestGen Advisors held 12,221 shares of Eli Lilly worth $14.1M as of Q3 2026.
  • VestGen Advisors sold 550 Eli Lilly shares in Q3 2026, an estimated $649K.
  • Eli Lilly made up 0.44% of VestGen Advisors's portfolio in Q3 2026, its #47 holding.
  • VestGen Advisors first reported a position in Eli Lilly in Q1 2025 and has held it in 7 quarters since.
  • VestGen Advisors's Eli Lilly position peaked at $15.3M in Q2 2026.
  • 2,846 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on VestGen Advisors's 13F filing for Q3 2026, filed 27 Oct 2026.